Salmeterol administration by metered-dose inhaler alone vs metered-dose inhaler plus valved holding chamber

Kutay Demirkan, Elizabeth Tolley, Terrye Mastin, Judith Soberman, Joy Burbeck, Timothy Self

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Study objective: To determine whether a spacer device designed as a valved holding chamber with a flow signal increases the efficacy of the long- acting β2-agonist, salmeterol, in patients who use incorrect technique with metered-dose inhaler (MDI) alone. Design: Double-blind, randomized, placebo- controlled study. Setting: University hospital outpatient rooms. Patients: Twenty adult outpatients with stable persistent asthma, receiving a daily anti-inflammatory drug. Interventions: Patients were randomized to either salmeterol MDI (incorrect use: 1 s after actuating MDI, inhale rapidly) and placebo plus spacer (correct use: inhale slowly as MDI is actuated, continue to inhale slowly and deeply) or placebo MDI (incorrect use) and salmeterol plus spacer (correct use). The following week, patients received the opposite treatment. The dose was two puffs from each device on each treatment day; each puff was separated by 1 min. Measurements and results: After baseline peak expiratory flow (PEF), salmeterol was administered and serial PEF determined (0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h). Administration of salmeterol MDI plus spacer resulted in significantly greater increases in PEF from baseline vs MDI at 4 h (44 L/min vs 10 L/min; p < 0.01) and 6 h (49 L/min vs 24 L/min; p < 0.05). Both methods of administration were equally well tolerated. Conclusion: We conclude that patients who have poor timing and rapid inhalation with salmeterol MDI alone will have greater increases in PEF at 4 h and 6 h and no additional side effects if the dose is administered with a valved holding chamber that is used correctly. Further study is needed regarding other errors in MDI technique with salmeterol.

Original languageEnglish (US)
Pages (from-to)1314-1318
Number of pages5
JournalChest
Volume117
Issue number5
DOIs
StatePublished - Jan 1 2000

Fingerprint

Inhalation Spacers
Metered Dose Inhalers
Placebos
Outpatients
Salmeterol Xinafoate
Equipment and Supplies
Inhalation
Anti-Inflammatory Agents
Asthma

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Salmeterol administration by metered-dose inhaler alone vs metered-dose inhaler plus valved holding chamber. / Demirkan, Kutay; Tolley, Elizabeth; Mastin, Terrye; Soberman, Judith; Burbeck, Joy; Self, Timothy.

In: Chest, Vol. 117, No. 5, 01.01.2000, p. 1314-1318.

Research output: Contribution to journalArticle

Demirkan, Kutay ; Tolley, Elizabeth ; Mastin, Terrye ; Soberman, Judith ; Burbeck, Joy ; Self, Timothy. / Salmeterol administration by metered-dose inhaler alone vs metered-dose inhaler plus valved holding chamber. In: Chest. 2000 ; Vol. 117, No. 5. pp. 1314-1318.
@article{b084db68febe488d84cbdf8085a4c8a0,
title = "Salmeterol administration by metered-dose inhaler alone vs metered-dose inhaler plus valved holding chamber",
abstract = "Study objective: To determine whether a spacer device designed as a valved holding chamber with a flow signal increases the efficacy of the long- acting β2-agonist, salmeterol, in patients who use incorrect technique with metered-dose inhaler (MDI) alone. Design: Double-blind, randomized, placebo- controlled study. Setting: University hospital outpatient rooms. Patients: Twenty adult outpatients with stable persistent asthma, receiving a daily anti-inflammatory drug. Interventions: Patients were randomized to either salmeterol MDI (incorrect use: 1 s after actuating MDI, inhale rapidly) and placebo plus spacer (correct use: inhale slowly as MDI is actuated, continue to inhale slowly and deeply) or placebo MDI (incorrect use) and salmeterol plus spacer (correct use). The following week, patients received the opposite treatment. The dose was two puffs from each device on each treatment day; each puff was separated by 1 min. Measurements and results: After baseline peak expiratory flow (PEF), salmeterol was administered and serial PEF determined (0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h). Administration of salmeterol MDI plus spacer resulted in significantly greater increases in PEF from baseline vs MDI at 4 h (44 L/min vs 10 L/min; p < 0.01) and 6 h (49 L/min vs 24 L/min; p < 0.05). Both methods of administration were equally well tolerated. Conclusion: We conclude that patients who have poor timing and rapid inhalation with salmeterol MDI alone will have greater increases in PEF at 4 h and 6 h and no additional side effects if the dose is administered with a valved holding chamber that is used correctly. Further study is needed regarding other errors in MDI technique with salmeterol.",
author = "Kutay Demirkan and Elizabeth Tolley and Terrye Mastin and Judith Soberman and Joy Burbeck and Timothy Self",
year = "2000",
month = "1",
day = "1",
doi = "10.1378/chest.117.5.1314",
language = "English (US)",
volume = "117",
pages = "1314--1318",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "5",

}

TY - JOUR

T1 - Salmeterol administration by metered-dose inhaler alone vs metered-dose inhaler plus valved holding chamber

AU - Demirkan, Kutay

AU - Tolley, Elizabeth

AU - Mastin, Terrye

AU - Soberman, Judith

AU - Burbeck, Joy

AU - Self, Timothy

PY - 2000/1/1

Y1 - 2000/1/1

N2 - Study objective: To determine whether a spacer device designed as a valved holding chamber with a flow signal increases the efficacy of the long- acting β2-agonist, salmeterol, in patients who use incorrect technique with metered-dose inhaler (MDI) alone. Design: Double-blind, randomized, placebo- controlled study. Setting: University hospital outpatient rooms. Patients: Twenty adult outpatients with stable persistent asthma, receiving a daily anti-inflammatory drug. Interventions: Patients were randomized to either salmeterol MDI (incorrect use: 1 s after actuating MDI, inhale rapidly) and placebo plus spacer (correct use: inhale slowly as MDI is actuated, continue to inhale slowly and deeply) or placebo MDI (incorrect use) and salmeterol plus spacer (correct use). The following week, patients received the opposite treatment. The dose was two puffs from each device on each treatment day; each puff was separated by 1 min. Measurements and results: After baseline peak expiratory flow (PEF), salmeterol was administered and serial PEF determined (0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h). Administration of salmeterol MDI plus spacer resulted in significantly greater increases in PEF from baseline vs MDI at 4 h (44 L/min vs 10 L/min; p < 0.01) and 6 h (49 L/min vs 24 L/min; p < 0.05). Both methods of administration were equally well tolerated. Conclusion: We conclude that patients who have poor timing and rapid inhalation with salmeterol MDI alone will have greater increases in PEF at 4 h and 6 h and no additional side effects if the dose is administered with a valved holding chamber that is used correctly. Further study is needed regarding other errors in MDI technique with salmeterol.

AB - Study objective: To determine whether a spacer device designed as a valved holding chamber with a flow signal increases the efficacy of the long- acting β2-agonist, salmeterol, in patients who use incorrect technique with metered-dose inhaler (MDI) alone. Design: Double-blind, randomized, placebo- controlled study. Setting: University hospital outpatient rooms. Patients: Twenty adult outpatients with stable persistent asthma, receiving a daily anti-inflammatory drug. Interventions: Patients were randomized to either salmeterol MDI (incorrect use: 1 s after actuating MDI, inhale rapidly) and placebo plus spacer (correct use: inhale slowly as MDI is actuated, continue to inhale slowly and deeply) or placebo MDI (incorrect use) and salmeterol plus spacer (correct use). The following week, patients received the opposite treatment. The dose was two puffs from each device on each treatment day; each puff was separated by 1 min. Measurements and results: After baseline peak expiratory flow (PEF), salmeterol was administered and serial PEF determined (0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h). Administration of salmeterol MDI plus spacer resulted in significantly greater increases in PEF from baseline vs MDI at 4 h (44 L/min vs 10 L/min; p < 0.01) and 6 h (49 L/min vs 24 L/min; p < 0.05). Both methods of administration were equally well tolerated. Conclusion: We conclude that patients who have poor timing and rapid inhalation with salmeterol MDI alone will have greater increases in PEF at 4 h and 6 h and no additional side effects if the dose is administered with a valved holding chamber that is used correctly. Further study is needed regarding other errors in MDI technique with salmeterol.

UR - http://www.scopus.com/inward/record.url?scp=0034033625&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034033625&partnerID=8YFLogxK

U2 - 10.1378/chest.117.5.1314

DO - 10.1378/chest.117.5.1314

M3 - Article

C2 - 10807816

AN - SCOPUS:0034033625

VL - 117

SP - 1314

EP - 1318

JO - Chest

JF - Chest

SN - 0012-3692

IS - 5

ER -